Myopia and Presbyopia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Myopia And Presbyopia Treatment Market is projected to expand significantly, growing from USD 21.95 Billion in 2025 to USD 35.38 Billion by 2031, reflecting a compound annual growth rate of 8.28%. This industry encompasses a broad range of corrective medical solutions, including prescription eyeglasses, contact lenses, refractive surgeries, and pharmacological agents designed to rectify nearsightedness and age-related vision loss. The sector's growth is primarily fueled by demographic shifts, such as an aging global population, and the rising prevalence of myopia linked to lifestyle factors like increased digital consumption and reduced outdoor activity. Additionally, a strong latent consumer demand for spectacle independence serves as a powerful catalyst for adopting modern corrective technologies; for instance, 2024 data from the Contact Lens Institute indicated that 47.8 percent of glasses wearers who had never tried contact lenses were highly interested in doing so, revealing a substantial opportunity for market penetration.

However, the market faces a significant hurdle regarding the prohibitive cost and limited accessibility of advanced corrective procedures, particularly in emerging economies. The substantial financial investment required for premium refractive surgeries and specialized management devices restricts their adoption largely to wealthier demographics, thereby slowing growth in developing regions where healthcare infrastructure is less established. Consequently, while demand exists, economic barriers prevent broader expansion in these markets.

Market Drivers

The escalating global prevalence of myopia and presbyopia is fundamentally reshaping the treatment landscape and serving as a primary catalyst for market growth. This surge is increasingly connected to lifestyle factors such as rapid urbanization and intense digital consumption, which have accelerated the onset of refractive errors in younger demographics. As a result, there is a heightened urgency for effective management strategies that go beyond traditional corrective eyewear, driving the adoption of specialized control lenses and interventions. Underscoring this critical public health challenge, the Association of Optometrists reported in their October 2024 article, 'Examining the global prevalence of myopia,' that researchers estimated the current global prevalence of myopia among children and young people to be 30.47%, a figure that is compelling manufacturers to innovate rapidly.

Concurrently, the emergence of novel pharmacological therapies and corrective eye drops is revolutionizing patient care by offering non-invasive alternatives to surgery and spectacles. Recent commercial launches of presbyopia-correcting drops and low-dose atropine for myopia indicate a significant shift toward pharmaceutical management of vision impairment, supported by substantial capital inflows aimed at commercializing these solutions. For example, Optometry Times reported in October 2024 that Orasis Pharmaceuticals secured $78 million in financing to support the commercial launch of Qlosi. This robust investment climate highlights the sector's financial vitality, further evidenced by The Vision Council's report that the U.S. optical industry achieved a total market value of $68.3 billion in 2024.

Market Challenges

The prohibitive cost and limited accessibility of advanced corrective procedures constitute a primary obstruction to the expansion of the global market. High financial barriers associated with premium refractive surgeries and specialized pharmacological agents effectively restrict the adoption of these solutions to affluent demographics. This economic stratification prevents the mass market, particularly in developing nations, from transitioning away from traditional, lower-cost correctives like standard eyeglasses. Consequently, the addressable market size is artificially capped, as a vast majority of the patient population cannot afford the significant out-of-pocket leverage required for modern interventions, despite the clinical benefits they offer.

This challenge is exacerbated by the substantial price tag attached to elective procedures, which often lack comprehensive insurance coverage. According to the Refractive Surgery Council, in 2024, the average cost of LASIK eye surgery was approximately $4,400 for a bilateral procedure. Such a high price point is prohibitive in emerging economies where disposable income is limited and healthcare infrastructure is often insufficient to support widespread access to such specialized treatments. As a result, market penetration in these high-growth potential regions remains sluggish, hampering the overall revenue trajectory of the industry.

Market Trends

The proliferation of next-generation myopia control spectacle lenses is establishing a new standard of care for pediatric patients, moving beyond traditional single-vision correction. These advanced lenses utilize specialized optical defocus technologies to actively slow eyeball elongation, contrasting with standard glasses that merely correct refractive error. This shift is driven by clinical evidence of their efficacy, prompting adoption as a primary non-invasive intervention. The commercial success of these products highlights their growing importance in the treatment mix; according to EssilorLuxottica's 'Q4/Full Year 2024 Results' press release in February 2025, revenue for Stellest lenses increased by approximately 50% in China during the fourth quarter.

Advancements in Implantable Collamer Lens (ICL) technologies are simultaneously expanding surgical options for high myopia patients often unsuitable for corneal laser procedures. This reflects a technological pivot from subtractive techniques like LASIK to additive solutions that preserve corneal integrity. Manufacturers are enhancing these devices with wider refractive ranges, increasing surgeon confidence and patient acceptance. This segment is witnessing robust financial performance as procedure volumes rise; according to the 'STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025' press release in October 2025, the company reported preliminary net sales of $94.7 million, representing a 6.9% increase compared to the prior year period.

Key Players Profiled in the Myopia And Presbyopia Treatment Market

• Ziemer Ophthalmic Systems AG
• NIDEK CO., LTD.
• Johnson & Johnson Vision
• EssilorLuxottica.
• ZEISS Group
• Alcon Vision LLC
• Bausch + Lomb Corporation
• Haag-Streit UK
• Topcon Corporation

Report Scope

In this report, the Global Myopia And Presbyopia Treatment Market has been segmented into the following categories:

Myopia And Presbyopia Treatment Market, by Myopia Treatment Type:

• Corrective
• Surgical
• Drugs

Myopia And Presbyopia Treatment Market, by Presbyopia Treatment Type:

• Prescription
• Contact Lenses
• Intraocular Lenses
• Refractive Surgery

Myopia And Presbyopia Treatment Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Myopia And Presbyopia Treatment Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.